Cover Image
Market Research Report

Middle East and Turkey Hemophilia Treatment Market, by Product Type, by Disease Indication, and by Country - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published by Coherent Market Insights Product code 920713
Published Content info 185 Pages
Delivery time: 2-3 business days
Price
Back to Top
Middle East and Turkey Hemophilia Treatment Market, by Product Type, by Disease Indication, and by Country - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
Published: January 3, 2020 Content info: 185 Pages
Description

Title:
Middle East and Turkey Hemophilia Treatment Market, by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027.

Hemophilia is rare disorder, in which in which the blood does not clot properly. In this case, bleeding after an injury takes longer duration to clot. This condition is well treated with medications such as recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Generally hemophilia occurs in middle age and geriatric population, and in women after child birth. Hemophilia is characterized by the lower levels of factors in the blood, which results in constant bleeding for longer duration after an injury.

Market Dynamics:

  • Increasing incidences of hemophilia cases is expected to drive the Middle East and Turkey hemophilia treatment market growth. For instance, according to the Annual Global Survey's 2016 data published by World Federation of Hemophilia, around 184,723 number of people globally suffered from hemophilia in 2016. Among this, 149,764 and 29,712 patients accounted for Hemophilia A and Hemophilia B, respectively.
  • Rising collaboration activities among the key players in pharmaceutical industry to develop novel hemophilia treatment options is expected to drive growth of the market. For instance, in May 2017, Sangamo Therapeutics, Inc. and Pfizer Inc. entered into a collaboration for the development and commercialization of Hemophilia A gene therapy programs, which include Sangamo's SB-525 candidate, which may benefit patients suffering from Hemophilia A.

Key features of the study::

  • This report provides in-depth analysis of the Middle East and Turkey hemophilia treatment, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019-2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the Middle East and Turkey hemophilia treatment based on the following parameters - company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The Middle East and Turkey hemophilia treatment report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for Middle East and Turkey hemophilia treatment, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation::

  • Middle East and Turkey Hemophilia Treatment, By Product Type:
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
  • Middle East and Turkey Hemophilia Treatment, By Disease Indication:
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Middle East and Turkey Hemophilia Treatment, By Country:
  • Turkey
    • By Product Type:
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
    • By Disease Indication:
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Egypt
    • By Product Type:
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
    • By Disease Indication:
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Israel
    • By Product Type:
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
    • By Disease Indication:
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Saudi Arabia
    • By Product Type:
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
    • By Disease Indication:
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Rest of Latin America
  • UAE
    • By Product Type:
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
    • By Disease Indication:
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Rest of Middle East
    • By Product Type:
  • Recombinant Coagulation Factor
  • Plasma Derived Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
    • By Disease Indication:
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Company Profiles
    • Takeda Pharmaceutical Company Limited*.
  • Company Overview
  • Technology Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
    • Sanofi S.A.
    • Octapharma AG
    • Swedish Orphan Biovitrum AB
    • Baxter International Inc.
    • Biogen Inc.
    • Bayer AG
    • CSL Behring
    • Ferring B.V.
    • Pfizer, Inc.
    • Kedrion
    • Novo Nordisk A/S
    • Grifols S.A
    • Sangamo Therapeutics, Inc.
    • Spark Therapeutics, Inc.
  • "*" marked represents similar segmentation in other categories in the respective section.
Table of Contents

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Disease Indication
    • Market Snippet, By Country
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Technology Advancements
  • Historical Overview
  • Merger and Acquisition
  • Regulatory Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Middle East and Turkey Hemophilia Treatment Market, By Product Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Recombinant Coagulation Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Plasma Derived Coagulation Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Antifibrinolytic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Desmopressin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

5. Middle East and Turkey Hemophilia Treatment Market, By Disease Indication, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hemophilia A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Hemophilia B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Hemophilia C
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Middle East and Turkey Hemophilia Treatment Market, By Country, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Country, 2018 and 2027 (%)
    • Y-o-Y Growth Analysis, By Country, 2016 - 2027
    • Regional Trends
  • Turkey
    • Market Size and Forecast, By Product Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
  • Egypt
    • Market Size and Forecast, By Product Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
  • Israel
    • Market Size and Forecast, By Product Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
  • Saudi Arabia
    • Market Size and Forecast, By Product Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
  • UAE
    • Market Size and Forecast, By Product Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
  • Rest of Middle East
    • Market Size and Forecast, By Product Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Takeda Pharmaceutical Company Limited.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Octapharma AG
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Swedish Orphan Biovitrum AB
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Baxter International Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biogen Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bayer AG
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • CSL Behring
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Ferring B.V.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Kedrion
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novo Nordisk A/S
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Grifols S.A
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sangamo Therapeutics, Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Spark Therapeutics, Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top